A new option for colorectal cancer screening is now available in Nevada, offering a different path for people who have put off traditional tests.
A blood-based screening test called Shield is now being offered through Quest Diagnostics, allowing doctors to order the test for adults aged 45 and older who are considered average risk.
The test, developed by Guardant Health, was approved by the FDA and is designed to detect signals associated with colorectal cancer through a standard blood draw, rather than a colonoscopy or stool-based test.
People can have the blood drawn at Quest patient service centers across Nevada, including locations in Reno and Carson City, along with sites in Southern Nevada. The test is also available at some doctors’ offices and other participating labs. Because it is offered by prescription only, people are advised to check with their doctor about whether it is appropriate for them and where it is available.
Guardant Health says Quest Diagnostics’ is one of the largest networks in Nevada, which expands access to the test across the state.
Colorectal cancer remains the second leading cause of cancer deaths in Nevada, according to the American Cancer Society. Screening rates have been a concern, in part because some people avoid tests that are seen as inconvenient or uncomfortable.
The new test is intended to offer a simpler option that may increase participation in screening.
“Activating our strategic collaboration with Quest marks a pivotal milestone in broadening access to Shield and empowering primary care physicians across the country to bring the lifesaving advantages of early detection to their patients with just a blood draw,” said AmirAli Talasaz, Guardant Health co-CEO. “Shield’s innovative technology supported by Quest’s vast, nationwide infrastructure will strengthen our ability to fundamentally transform colorectal cancer screening by equipping doctors with a quick, easier screening option that patients are far more likely to complete.”
Data from the National Colorectal Cancer Roundtable shows disparities in screening and outcomes among some groups. Some groups experience higher rates of diagnosis and mortality and are more likely to be diagnosed at younger ages and at later stages.
When colorectal cancer is detected early, the five-year survival rate is about 91%, according to Guardant Health.
The Shield test is covered by Medicare and the Veterans Affairs Community Care Network and is available commercially. Doctors who already work with Quest can order the test through existing systems, including electronic health records.
Health providers say the goal is to make screening more accessible, especially for people who have delayed testing.
